Screening for fetal aneuploidy

Seminars in Perinatology

Volumn 40, Issue 1, 2016, Pages 35-43

  Rink, Britton D ^a   Norton, Mary E ^b  

^a Mount Carmel Health Systems   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cell free fetal DNA; Chromosomal aneuploidy; Genetic testing; Prenatal genetic counseling; Prenatal screening; Prenatal ultrasound

Indexed keywords

ALPHA FETOPROTEIN; CELL FREE FETAL DNA; CHORIONIC GONADOTROPIN; DNA; UNCLASSIFIED DRUG; PAPPA1 PROTEIN, HUMAN; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ANEUPLOIDY; CYSTIC LYMPHANGIOMA; DNA SCREENING; DOWN SYNDROME; FALSE POSITIVE RESULT; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; GENETIC COUNSELING; GENETIC SCREENING; HUMAN; MATERNAL AGE; MULTIPLE PREGNANCY; NUCHAL TRANSLUCENCY MEASUREMENT; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PRENATAL DIAGNOSIS; PRENATAL SCREENING; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SECOND TRIMESTER PREGNANCY; SINGLE NUCLEOTIDE POLYMORPHISM; THIRD TRIMESTER PREGNANCY; TRISOMY 21; AMNIOCENTESIS; BLOOD; CHORION VILLUS SAMPLING; CHROMOSOME 13; CHROMOSOME 18; CHROMOSOME DISORDERS; FEMALE; FETUS; GENETICS; METABOLISM; PREGNANCY; PROCEDURES; TRISOMY; TURNER SYNDROME;

ALPHA-FETOPROTEINS; AMNIOCENTESIS; ANEUPLOIDY; CHORIONIC GONADOTROPIN; CHORIONIC VILLI SAMPLING; CHROMOSOME DISORDERS; CHROMOSOMES, HUMAN, PAIR 13; CHROMOSOMES, HUMAN, PAIR 18; DNA; DOWN SYNDROME; FEMALE; FETUS; GENETIC COUNSELING; HUMANS; MATERNAL AGE; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PRENATAL DIAGNOSIS; TRISOMY; TURNER SYNDROME; ULTRASONOGRAPHY, PRENATAL;

EID: 84959173516     PISSN: 01460005     EISSN: 1558075X     Source Type: Journal    
DOI: 10.1053/j.semperi.2015.11.006     Document Type: Review

References (77)

1. Savva G.M., Morris J.K., Mutton D.E., Alberman E. Maternal age-specific fetal loss rates in Down syndrome pregnancies. Prenat Diagn 2006, 26(6):499.
2. Antonarakis S.E. Parental origin of the extra chromosome in trisomy 21 as indicated by analysis of DNA polymorphisms. Down Syndrome Collaborative Group. N Engl J Med 1991, 324(13):872.
3. ACOG Practice Bulletin No.77 Screening for fetal chromosomal abnormalities. Obstet Gynecol 2007, 109(1):217-227.
4. Warsof S.L., Larion S., Abuhamad A.Z. Overview of the impact of noninvasive prenatal testing on diagnostic procedures. Prenat Diagn 2015, 35(10):1-8.
5. Nicolaides K.H., Azar G., Byrne D., Mansur C., Marks K. Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy. Br Med J 1992, 304(6831):867-869.
6. Wald N.J., Rodeck C., Hackshaw A.K., Walters J., Chitty L., Mackinson A.M. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen 2003, 10(2):56-104.
7. Malone F.D., Canick J.A., Ball R.H., et al. First- and Second-Trimester Evaluation of Risk (FASTER) Research Consortium. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 2005, 353(19):2001-2011.
8. Wapner R., Thom E., Simpson J.L., et al. First-trimester screening for trisomies 21 and 18. N Engl J Med 2003, 349(15):1405-1413.
9. Malone F.D., Ball R.H., Nyberg D.A., et al. First-trimester septated cystic hygroma: prevalence, natural history and pediatric outcome. Obstet Gynecol 2005, 106(2):288.
10. Molina F.S., Avgidou K., Kagan K.O., Poggi S., Nicolaides K.H. Cystic hygroma, nuchal edema and nuchal translucency at 11-14 weeks of gestation. Obstet Gynecol 2006, 107(3):678-683.
11. Baer R.J., Norton M.E., Shaw G.M., et al. Risk of selected structural abnormalities in infants after increased nuchal translucency measurement. Am J Obstet Gynecol 2014, 211(6):675e1-675e19.
12. Makrydimas G., Sotiriadis A., Ioannidis J.P. Screening performance of first-trimester nuchal translucency for major cardiac defects: a meta-analysis. Am J Obstet Gynecol 2003, 189(5):1330-1335.
13. Jelliffe-Pawlowski L.L., Norton M.E., Shaw G.M., et al. Risk of critical congenital heart defects by nuchal translucency norms. Am J Obstet Gynecol 2015, 212(4):518e1-518e10.
14. Spencer K., Souter V., Tul N., et al. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 1999, 13(4):231-237.
15. Wald N.J., Hackshaw A.K. Combining ultrasound and biochemistry in first-trimester screening for Down syndrome. Prenat Diagn 1997, 17(9):821.
16. Canick J.A., Lambert-Messerlian G.M., Palomaki G.E., et al. Comparison of serum markers in first-trimester Down syndrome screening. Obstet Gynecol 2006, 108(5):1192.
17. Nicolaides K.H. Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities. Am J Obstet Gynecol 2004, 191(1):45.
18. Bilrdo C.M., Muller M.A., Pajkrt E., et al. Increased nuchal translucency thickness and normal karyotype: time for parental reassurance. Ultrasound Obstet Gynecol 2007, 30(1):11-18.
19. Souka A.P., von Kaisenberg C.S., Hyett J.A., Sonek J.A., Nicolaides K.H. Increased nuchal translucency with normal karyotype. Am J Obstet Gynecol 2005, 192(4):1005-1021.
20. Snijders R.J., Noble P., Sabire N., Souka A., Nicolaides K.H. A multicentre project on assessment of risk for trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks gestation. Fetal Medicine Foundation First Trimester screening Group. Lancet 1998, 352(9125):343-346.
21. Cicero S., Rembouskos G., Vandecruys H., Hogg M., Nicolaides K.H. Likelihood ratio for trisomy 21 in fetuses with absent nasal bone at the 11-14-week scan. Ultrasound Obstet Gynecol 2004, 23(3):218-223.
22. Ghaffari S.R., Tahmasebpour A.R., Jamal A., et al. First trimester screening for chromosomal abnormalities by integrated application of nuchal translucency, nasal bone, tricuspid regurgitation and ductus venosus flow combined with maternal serum free-beta hCG and PAPP-A: a 5-year prospective study. Ultrasound Obstet Gynecol 2012, 39(5):528-534.
23. Wald N.J., Cuckle H.S. Biochemical screening. Prenatal Diagnosis and Screening 1992, 556. Churchill Livingstone, Edinburgh. D.J.H. Brock, C.H. Rodeck, M.A. Ferguson-Smith (Eds.).
24. Merkatz I.R., Nitowsky H.M., Macri J.N., et al. An association between low maternal serum alpha-fetoprotein and fetal chromosome abnormalities. Am J Obstet Gynecol 1984, 148(7):886.
25. Cuckle H.S., Wald N.J., Lindenbaum R.H. Cord serum alpha-fetoprotein and Down syndrome. Br J Obstet Gynaecol 1986, 93(4):407.
26. Jorgensen P.I., Trolle D. Low urinary oestriol excretion during pregnancy in women giving birth to infants with Down syndrome. Lancet 1972, 2(7781):782.
27. Bogart M.H., Pandian M.R., Jones O.W. Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities. Prenat Diagn 1987, 7(9):623.
28. Lambert-Messerlian G.M., Canick J.A., Palomaki G.E., et al. Second trimester levels of maternal serum inhibin A, total inhibin, alpha inhibin precursor, and activin in Down syndrome pregnancy. J Med Screening 1996, 3(2):58.
29. Wallace E.M., Swanston I.A., McNeilly A.S., et al. Second trimester screening for Down syndrome using maternal serum dimeric inhibin A. Clin Endocrinol 1996, 44(1):17.
30. Canick J.A., MacRae A.R. Second trimester serum markers. Semin Perinatol 2005, 29(4):203.
31. Wald N.J., Kennard A., Hackshaw A., McGuire A. Antenatal screening for Down's syndrome. J Med Screen 1997, 4(4):181-246.
32. Palomaki G.E., Knight G.J., Haddow J.E., et al. Prospective trial of a screening protocol to identify trisomy 18 using maternal serum alpha-fetoprotein, unconjugated estriol, and human chorionic gonadotropin. Prenat Diagn 1991, 49(suppl):227.
33. Watt H.C., Wald N.J., Smith D., Kennard A., Densem J. Effect of allowing for ethnic group in prenatal screening for Down's syndrome. Prenat Diagn 1996, 16(10):691-698.
34. Spencer K., Ong C.Y., Liao A.W., Nicolaides K.H. The influence of ethnic origin on first trimester biochemical markers of chromosomal abnormalities. Prenat Diagn 2000, 20(6):491-494.
35. Huttly W., Rudnicka A., Wald N.J. Second-trimester prenatal screening markers for Down syndrome in women with insulin-dependent diabetes mellitus. Prenat Diagn 2004, 24(10):804-807.
36. Wald N.J., White N., Morris J.K., Huttly W.J., Canick J.A. Serum markers for Down's syndrome in women who have had in vitro fertilization: implications for antenatal screening. Br J Obstet Gynaecol 1999, 106(12):1304-1306.
37. Cuckle H., Benn P., Wright D. Down syndrome screening in the first and/or second trimester: model predicted performance using meta-analysis parameters. Semin Perinatol 2005, 29(4):252-257.
38. Robinson L., Grau P., Crandall B.F. Pregnancy outcomes after increasing levels of maternal serum alpha-fetoprotein. Obstet Gynecol 1989, 74(1):17.
39. Zelop C., Nadel A.S., Frigoletto F., et al. Placenta accreta, percreta and increta: a cause of increased maternal serum alpha-fetoprotein. Obstet Gynecol 1992, 80(4):693.
40. Heinonen S., Ryynanen M., Kirkinen P., et al. Uterine malformation: a cause of elevated maternal serum alpha-fetoprotein concentrations. Prenat Diagn 1996, 16(7):635.
41. Palacio M., Jauniaux E., Kingdom J., et al. Perinatal outcome in pregnancies with a positive serum screening for Down's syndrome due to elevated levels of free beta-human chorionic gonadotropin. Ultrasound Obstet Gynecol 1999, 13(1):58.
42. Dugoff L., Hobbins J.C., Malone F.D., et al. FASTER Trial Research Consortium. Quad screen as a predictor of adverse pregnancy outcome. Obstet Gynecol 2005, 106(2):260.
43. Lepage N., Chitayat D., Kingdom J., Huang T. Association between second-trimester isolated high maternal serum maternal serum human chorionic gonadotropin levels and obstetric complications in singleton and twin pregnancies. Am J Obstet Gynecol 2003, 188(5):1354.
44. Onderoglu L.S., Kabukcu A. Elevated second trimester human chorionic gonadotropin level associated with adverse pregnancy outcome. Int J Gynaecol Obstet 1997, 56(3):245.
45. Duric K., Skrablin S., Lesin J., et al. Second trimester total human chorionic gonadotropin, alpha-fetoprotein and unconjugated estriol in predicting pregnancy complications other than fetal aneuploidy. Eur J Obstet Gynecol Reprod Biol 2003, 110(1):12.
46. Kowalczyk T.D., Cabaniss M.L., Cusmano L. Association of low unconjugated estriol in the second trimester and adverse pregnancy outcome. Obstet Gynecol 1998, 91(3):396.
47. Kelley R.I. Inborn errors of cholesterol biosynthesis. Adv Pediatr 2000, 47:1.
48. Kratz L.E., Kelley R.I. Prenatal diagnosis of the RSH/Smith-Lemli-Opitz syndrome. Am J Med Genet 1999, 82(5):376.
49. Schoen E., Norem C., O'Keefe J., et al. Maternal serum unconjugated estriol as a predictor for Smith-Lemli-Opitz syndrome and other fetal conditions. Obstet Gynecol 2003, 102(1):167.
50. Kashork C.D., Sutton V.R., Fonda Allen J.S., et al. Low or absent unconjugated estriol in pregnancy: an indicator for steroid sulfatase deficiency detectable by fluorescence in situ hybridization and biochemical analysis. Prenat Diagn 2002, 22(11):1028.
51. Bradley L.A., Canick J.A., Palomaki G.E., Haddow J.E. Undetectable maternal serum unconjugated estriol levels in the second trimester: risk of perinatal complications associated with placental sulfatase deficiency. Am J Obstet Gynecol 1997, 176(3):531.
52. Dugoff L. First and second-trimester maternal serum markers for aneuploidy and adverse obstetric outcomes. Obstet Gynecol 2010, 115(5):1052-1061.
53. Aagaard-Tillery K.M., Malone F.D., Nyberg D.A., et al. Role of second-trimester genetic sonography after Down syndrome screening. Obstet Gynecol 2009, 114(6):1189.
54. Agathokleous M., Chaveeva P., Poon L.C.Y., et al. Meta-analysis of second trimester markers for trisomy 21. Ultrasound Obstet Gynecol 2013, 41(3):247.
55. Walknowska J., Conte F.A., Grumbach M.M. Practical and theoretical implications of fetal-maternal lymphocyte transfer. Lancet 1969, 1(7606):1119-1122.
56. Lo Y.M., Corbetta N., Chamberlain P.F., et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997, 350(9067):485-487.
57. Norton M.E., Brar H., Weiss J., et al. Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multi-center prospective cohort study for detection of fetal trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012, 207(2):137e1-137e8.
58. Zimmermann B., El-Sheikhah A., Nicolaides K., Holzgreve W., Hahn S. Optimized real-time quantitative PCR measurement of male fetal DNA in maternal plasma. Clin Chem 2005, 51(9):1598-1604.
59. Kolialexi A., Tounta G., Mavrou A. Noninvasive fetal RhD genotyping from maternal blood. Expert Rev Mol Diagn 2010, 10(3):285-296.
60. Committee Opinion No.545 American College of Obstetricians and Gynecologists. Noninvasive prenatal testing for fetal aneuploidy. Obstet Gynecol 2012, 120(6):1532-1534.
61. Mersy E., Smits L.J., Van Winden L.A., et al. Noninvasive detection of fetal trisomy 21: systematic review and report of quality and outcomes of diagnostic accuracy studies performed between 1997 and 2012. Human Reprod Update 2013, 19(4):318-329.
62. Dan S., Wang W., Ren J., et al. Clinical application of massively parallel sequencing-based prenatal noninvasive fetal trisomy test for trisomies 21 and 18 in 11,105 pregnancies with mixed risk factors. Prenat Diagn 2012, 32(13):1225-1232.
63. Bianchi D.W., Parker R., Wentworth J., et al. DNA sequencing versus standard prenatal aneuploidy screening. N Engl J Med 2014, 370(9):799-808.
64. Norton M.E., Rose N.C., Benn P. Noninvasive prenatal testing for fetal aneuploidy: clinical assessment and a plea for restraint. Obstet Gynecol 2013, 121(4):847-850.
65. Norton M.E., Jacobsson B., Swamy G.K., et al. Cell-free DNA analysis for noninvasive examination of trisomy. N Engl J Med 2015, 372(17):1589-1597.
66. Norton M.E., Jelliffee-Pawlowski L., Currier R.J. Chromosome abnormalities detected by current prenatal screening and noninvasive prenatal testing. Obstet Gynecol 2014, 124(5):979-986.
67. Brar H., Wang E., Struble C., Musci T., Norton M.E. The fetal fraction of cell-free DNA in maternal plasma is not affected by a priori of fetal trisomy. J Matern Fetal Neonatal Med 2013, 26(2):143-145.
68. Pergament E., Cuckle H., Zimmermann B., et al. Single-nucleotide polymorphism-based noninvasive prenatal screening in a high-risk and low-risk cohort. Obstet Gynecol 2014, 124(2 Pt 1):210-218.
69. Wapner R.J., Martin C.L., Levy B., et al. Chromosomal microarray versus karyotyping for prenatal diagnosis. N Engl J Med 2012, 367(23):2175-2184.
70. Morris S., Karlsen S., Chung N., Hill M., Chitty L.S. Model-based analysis of costs and outcomes of non-invasive prenatal testing for Down's Syndrome using cell free fetal DNA in the UK National Health Service. PloS One 2014, 9:e93559.
71. Cuckle H., Benn P., Pergament E. Maternal cfDNA screening for Down syndrome-a cost sensitivity analysis. Prenat Diagn 2013, 33(7):636-642.
72. Fan H.C., Gu W., Wang J., et al. Non-invasive prenatal measurement of the fetal genome. Nature 2012, 487(7407):320-324.
73. Boyle B., Morris J.K., McConkey R., et al. Prevalence and risk of Down syndrome in monozygotic and dizygotic multiple pregnancies in Europe: implications for prenatal screening. BJOG 2014, 121(7):809-820.
74. Cleary-Goldman J., Berkowitz R.L. First trimester screening for Down syndrome in multiple pregnancy. Semin Perinatol 2005, 29(6):312-320.
75. Wald N.J., Rish S., Hackshaw A.K. Combining nuchal translucency and serum markers in prenatal screening for Down syndrome in twin pregnancies. Prenat Diagn 2003, 23(7):5880592.
76. Maymon R., Rosen H., Baruchin O., Herman A., Cuckle H. Model predicted Down syndrome detection rates for nuchal translucency screening in twin pregnancies. Prenat Diagn 2011, 31(5):426-429.
77. Garchet-Beaudron A., Dreux S., Leporrier N., Oury J.F., Muller F. Second-trimester Down syndrome maternal serum marker screening: a prospective study of 11,040 twin pregnancies. Prenat Diagn 2008, 28(12):1105-1109.